Navigation Links
Ziegler is Pleased to Announce Its Role As the Exclusive Financial Advisor to Pathologists Bio-Medical Laboratories (PBM) on Its Recent Acquisition by PathGroup
Date:6/6/2019

Ziegler, a specialty investment bank, is pleased to announce its role as the exclusive financial advisor to Pathologists Bio-Medical Laboratories (PBM) on its recent acquisition by PathGroup.

Headquartered in Lewisville (Dallas), Texas, PBM is a preeminent anatomic pathology platform that provides services to more than one dozen hospitals and surgery centers in the Dallas-Fort Worth and broader Texas geographies through more than 40 board-certified and subspecialty pathologists. The platform’s subspecialty expertise includes Bone and Soft Tissue Pathology, Breast Pathology, Cytopathology, Forensic Pathology, Gastrointestinal Pathology, Hematopathology, Liver Pathology, Molecular Pathology, Nephropathology, Neuropathology, Pulmonary Pathology, and Urologic Pathology, among others.

PBM’s CAP- and CLIA-accredited laboratory in Lewisville will serve as the foundation for PathGroup’s accelerated expansion into the North Texas market, and PBM’s broad subspecialty expertise will complement PathGroup’s existing national pathology footprint. The combined company will include more than 120 pathologists, representing every subspecialty and creating one of the most comprehensive pathology networks in the country.

“PBM and PathGroup have similar histories of providing high-quality pathology services to patients, physicians and health systems,” said Peter A. Dysert, M.D., President of PBM. “Our like-minded cultures of physician leadership and private ownership will allow us to focus on what is best for the clients and patients we serve. We look forward to working with PathGroup and continuing to exceed the expectations of our hospitals and physician clients.”

Grant Chamberlain, Managing Director in Ziegler’s Healthcare Corporate Finance Practice stated, “This transaction concludes a decade long journey that we have had assisting PBM and Dr. Dysert through multiple transactions to keep PBM as one of the most respected, innovative and coveted AP practice in the country. We couldn’t be more pleased with the ideal cultural fit with PathGroup.”

Patrick Walsh, Director in Ziegler’s Healthcare Corporate Finance Practice added, “PBM is a great addition to the PathGroup family – a pathology practice that has kept its focus on patient care and consultative relationships with other physicians throughout its 55-plus year history; and PathGroup is the perfect partner for PBM as each continues to seek growth and navigate the constantly-changing role of laboratory services in the U.S. healthcare system.”

Ziegler's Corporate Finance team is focused on delivering best-in-class advisory and financing solutions for companies and organizations across the healthcare industry. In our core practice areas of healthcare services, information technology, hospitals and senior living, Ziegler is one of the most active M&A firms offering innovative sell-side, buy-side, recapitalization/restructuring, equity private placement and strategic partnering services.

For more information about Ziegler, please visit us at http://www.ziegler.com.

About Ziegler:
Ziegler is a privately held, national boutique investment bank, capital markets and proprietary investments firm. We have a unique focus on the healthcare, senior living and education sectors, as well as general municipal and structured finance. Headquartered in Chicago with regional and branch offices throughout the U.S., Ziegler provides its clients with capital raising, strategic advisory, fixed income sales & trading and research. To learn more, visit http://www.ziegler.com.

Certain comments in this news release represent forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995. This client’s experience may not be representative of the experience of other clients, nor is it indicative of future performance or success. The forward-looking statements are subject to a number of risks and uncertainties, in particular, the overall financial health of the securities industry, the strength of the healthcare sector of the U.S. economy and the municipal securities marketplace, the ability of the Company to underwrite and distribute securities, the market value of mutual fund portfolios and separate account portfolios advised by the Company, the volume of sales by its retail brokers, the outcome of pending litigation, and the ability to attract and retain qualified employees.

Read the full story at https://www.prweb.com/releases/ziegler_is_pleased_to_announce_its_role_as_the_exclusive_financial_advisor_to_pathologists_bio_medical_laboratories_pbm_on_its_recent_acquisition_by_pathgroup/prweb16359225.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. VetStem Biopharma is Pleased to Share the Success Story of Mandy, who was Treated with Stem Cell Therapy by Dr. Jerrold Bausman at VCA Vet Specialists of the Valley
2. VetStem Biopharma is Pleased to Share the Success Story of Sam Who was Treated with Stem Cell Therapy by Dr. Lucy Roberts at Animal Medical Center of Tuscaloosa
3. VetStem Biopharma is Pleased to Share the Success Story of Jack, a Great Pyrenees who was Treated with Stem Cell Therapy by Dr. Andrea Hayes
4. VetStem Biopharma is Pleased to Share the Success Story of Ava who was Treated with VetStem Cell Therapy by Dr. David Luck
5. Merck Animal Health announces Vetsulin
6. AAPS announces 2013 National Biotechnology Conference award winners
7. PLOS announces Accelerating Science Award Program
8. MARC travel awards announced for the 2013 60th Annual ACSM Meeting & 4th World Congress
9. DFG announces recipients of 2013 Heinz Maier-Leibnitz Prize
10. Missouri Botanical Garden program announces collaboration with LHerboretum
11. Scripps Research announces research & license agreement with Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2019)... ... May 22, 2019 , ... Leak Detection Associates (LDA), ... for the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries’ is excited to ... (IPP) Ltd has been signed. The agreement will grant exclusive rights for ...
(Date:5/21/2019)... ... , ... Suvoda LLC , a SaaS provider of Interactive Response Technology ... of Inc. Magazine’s Best Workplaces for 2019, Inc.’s fourth annual ranking of the fast-growing ... hitting the newsstands on May 28, is the result of a comprehensive measurement of ...
(Date:5/21/2019)... ... 20, 2019 , ... The ASGCT Clinical Trials Finder is a ... the United States. Data curated daily from ClinicalTrials.gov ensures the most up-to-date and applicable ... volunteered to assist in the development of the ASGCT Clinical Trials Finder ...
Breaking Biology News(10 mins):
(Date:5/4/2019)... PINE BROOK, N.J. (PRWEB) , ... May 03, ... ... visual electrophysiology, announces the release of the Diopsys® ffERG/Photopic Negative Response ... signs of glaucoma. , By 2050, it is estimated that 6.3 million Americans ...
(Date:5/2/2019)... ... 02, 2019 , ... Researchers from Ambry Genetics ... U.S. insurer policies for genetic testing and the 2019 National Comprehensive Cancer Network ... cancer (HBOC). , Jill S. Dolinsky, director of clinical affairs at ...
(Date:4/18/2019)... ... April 18, 2019 , ... ... research team that includes a chemical engineer at Worcester Polytechnic Institute (WPI) has ... may make it possible to manufacture isobutanol and other biofuels more economically. , ...
(Date:4/12/2019)... ... April 12, 2019 , ... An upcoming episode of Advancements ... innovative tools and devices being used to enhance cognitive skills. This episode is ... segment of Advancements will focus on Sound for Life, a neurotechnology company helping ...
Breaking Biology Technology: